Non-small Cell Lung Cancer With Central Nervous System Metastasis

Recruiting

• Conditions: Lung Cancer With Central Nervous System Metastasis
• Interventions: Other: lung cancer with brain /leptomeningeal metastasis

• Registration Number: NCT06026735
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-25
• Study Start: 2023-01-13
• Status Verified: 2023-08
• Study First Submitted QC: 2023-09-04
• Last Update Submitted: 2023-09-04
• Study First Posted: 2023-09-07
• Last Update Posted: 2023-09-07
• Primary Completion: 2027-12
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• A. Non-small cell lung cancer patients diagnosed with brain metastases or meningeal metastases on brain computed tomography (CT) or magnetic resonance (MRI) images.

B. Patients with non-small cell lung cancer who are about to undergo surgical brain surgery, such as brain tumor resection, lumbar abdominal drainage, Euclidean storage, or ventriculoperitoneal drainage.

Exclusion Criteria

• A. Non-small cell lung cancer patients without brain metastases or meningeal metastases.

B. Physical condition does not allow surgical removal of the tumor.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
lung cancer with leptomeningeal metastasis	lung cancer with brain /leptomeningeal metastasis	-
lung cancer with brain metastasis	lung cancer with brain /leptomeningeal metastasis	-

Primary Outcome Measures

Name	Time	Method
predict lung cancer metastasis and Bioindicators of treatment effect	follow 3 years	Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan